Clinical trial registry record

Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 2, 2018.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02507388
Last registry update
July 2, 2018
Status
Completed
Phase
Phase 2
Sponsor
Alcon Research
Enrollment
51
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · OTHER · DOUBLE
Evidence population
Human clinical study registration
Participants
51
Population
ALL · 50 Years
Duration
2015-08-24 to 2016-09-06
Intervention
Brolucizumab 3 mg/50 μL; Brolucizumab 6 mg/50 μL
Comparator
Not reported
Outcomes measured
Maximum Analyte Serum Concentration [Cmax (ng/mL)] — Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr; Time to Reach Maximum Analyte Serum Concentration [Tmax (h)] — Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504…; Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC0-t…; Area Under the Concentration-time Curve From 0 to Infinity [AUC0-inf (ng*h/mL)] — Day 0 (predose), 6 hr, 24 hr, 72 hr,…; Elimination Half-life in Serum [t1/2 (h)] — Day 0 (predose), 6 hr, 24 hr, 72 hr, 168 hr, 336 hr, 504 hr, 672 hr; Concentration of RTH258 Obtained 24 Hours Post Day 0 Injection [C24hr (ng/mL)] — Day 1; Concentration of RTH258 Obtained 24 Hours Post Day 56 Injection [C24hr (ng/mL)] — Day 57; Percentage of Subjects With Positive Anti-drug Antibody (ADA) Status (Test) — Day 0 (predose), Day 28, Day 84
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON